title: Prostaglandin E2 counteracts the effects of PGF2 alpha in indomethacin treated cycling gilts.
abstract: Twenty crossbred gilts with at least 2 consecutive estrous cycles of 18 to 21 days in length were used to study the effects of prostaglandins E2 and F2 alpha (PGE2 and PGF2 alpha) on luteal function in indomethacin (INDO) treated cycling gilts. Intrauterine and jugular vein catheters were surgically placed before day 7 of the treatment estrous cycle and gilts were randomly assigned to 1 of 5 treatment groups (4/group). With exception of the controls (Group I) all gilts received 3.3 mg/kg INDO every 8 h, Groups III, IV and V received 2.5 mg PGF2; 2.5 mg PGF2 alpha + 400 micrograms PGE2 every 4 hr, or 400 micrograms PGE2 every 4 h, respectively. All treatments were initiated on day 7 and continued until estrus or day 23. Jugular blood for progesterone analysis was collected twice daily from day 7 to 30. Estradiol-17 beta (E2-17 beta) concentrations were determined in samples collected twice daily, from 2 d before until 2 d following the day of estrus onset. When compared to pretreatment values, estrous cycle length was unaffected (P greater than 0.05) in Group I, prolonged (P less than 0.05) in Groups II, IV and V; and shortened (P less than 0.05) in Group III. The decline in plasma progesterone concentration that normally occurs around day 15 was unaffected (P greater than .05) in Group I; delayed (P less than 0.05) in Groups II, IV and V; and occurred early (P less than 0.05) in Group III. Mean E2-17 beta remained high (31.2 +/- 4.9 to 49.3 +/- 3.1 pg/ml) in Groups III and IV, while the mean concentrations in Groups III and V varied considerably (17.0 +/- 2.0 to 52.2 +/- 3.5 pg/ml). The results of this study have shown that PGE2 will counteract the effects of PGF2 alpha in INDO treated cycling gilts. The inclusion of PGF2 alpha appeared to either stimulate E2-17 beta secretion or maintain it at a higher level than other treatments.
authors.affiliation: Animal Science Department, Clemson University, SC 29634-0361.
authors.forename: B A
authors.initials: BA
authors.lastname: Akinlosotu
authors.forename: J R
authors.initials: JR
authors.lastname: Diehl
authors.forename: T
authors.initials: T
authors.lastname: Gimenez
mesh_terms: D000818:Animals; D015237:Dinoprost; D015232:Dinoprostone; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000187:drug effects*; D005260:Female; D011374:Progesterone / Q000097:blood; D011458:Prostaglandins E / Q000494:pharmacology*; D011460:Prostaglandins F / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013552:Swine / Q000502:physiology*
chemical_list: D011458:Prostaglandins E; D011460:Prostaglandins F; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost; D015232:Dinoprostone